Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
Status:
Completed
Trial end date:
2021-05-09
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the efficacy and safety of budesonide HFA
MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler) 100 mcg 4 puffs BID in Chinese
mild to moderate Asthma patients.
Phase:
Phase 4
Details
Lead Sponsor:
Intech Biopharm Ltd.
Collaborators:
Bao Gang Hospital Beijing Aicomer Pharmaceutical Technology Co., Ltd. Beijing Friendship Hospital Beijing Yi Hua Hospital Management Co., Ltd Daqing Oil Field Hospital First Affiliated Hospital of Jinan University GCP ClinPlus Co., Ltd. Healthcare Inc Jining Medical University Key Tech Meiheko Central Hospital Meizhou People's Hospital Peking University People's Hospital Qingdao Municipal Hospital Shaanxi Provincial People's Hospital The Affiliated Hospital of Inner Mongolia Medical University The First Affiliated Hospital of Shanxi Medical University The Second Hospital of Hebei Medical University Tianjin First Central Hospital